Efficacy of an Integrated Heartfulness Meditation and Yoga Protocol in Hypertensive Patients: A Randomized Controlled Study.

A 12-week program combining Heartfulness meditation and yoga reduced psychological distress and altered inflammatory and stress biomarkers in adults with prehypertension or Stage 1 hypertension. In this randomized controlled trial, the intervention group showed significant decreases in anxiety, depression, and somatization, along with reduced levels of pro-inflammatory cytokines IL-6, IL-1β, and TNF-α, increased anti-inflammatory IL-10, and lower stress markers copeptin and corticotropin. Correlations between psychological scores and biomarkers were modest. The authors conclude that the integrative practice improves well-being and modulates inflammatory and neuroendocrine markers, supporting its inclusion in hypertension management, while noting limitations including small sample size and short duration.

Study at a glance

Abstract

Hypertension is increasingly recognized as a biopsychosocial condition influenced by psychological distress and systemic inflammation. The potential of integrative mind-body approaches such as Heartfulness meditation and yoga to offer non-pharmacological benefits through neuroendocrine and immunomodulatory pathways is a source of hope and optimism in the field. To evaluate the effects of a 12-week Integrated Approach of Heartfulness-based Yogic Practices and Meditation (IAHFNM & YP) on psychological distress, inflammatory cytokines and stress biomarkers in individuals with prehypertension or Stage 1 hypertension. In this randomized controlled trial participants were allocated to either the intervention group (IAHFNM and YP) or the standard care group. Psychological distress was assessed using the Brief Symptom Inventory-18 (BSI-18). Blood samples were analyzed for cytokines (IL-6, IL-1β, TNF-α, IL-10, IL-18) and neuroendocrine stress markers (copeptin and corticotropin). The intervention group showed significant reductions in psychological distress, including anxiety, depression and somatization, as reflected by a marked decline in the Global Severity Index (P < .001). This reassures us about the study's effectiveness. Inflammatory biomarkers IL-6, IL-1β, and TNF-α significantly decreased (P < .05), while anti-inflammatory IL-10 levels increased (P < .001). Stress-related biomarkers copeptin and corticotropin also showed significant reductions (P < .001), suggesting downregulation of the hypothalamic-pituitary-adrenal (HPA) axis. Although correlations between psychological scores and biomarkers were modest (R2 < 0.12), corticotropin showed the strongest association with BSI-18 scores (r = 0.389). The findings demonstrate the efficacy of Heartfulness in improving psychological well-being and modulating inflammatory and neuroendocrine markers in prehypertension and hypertension. These results support integrating mind-body practices into hypertension management. However, small sample size, limited duration, and reliance on self-reported adherence may affect generalizability. Future studies with larger cohorts, objective adherence measures, and extended follow-up are recommended to establish sustainability and underlying mechanisms.